Last reviewed · How we verify
QTORIN 3.9% rapamycin anhydrous gel
QTORIN 3.9% rapamycin anhydrous gel is a topical immunomodulator that targets the mTOR pathway.
QTORIN 3.9% rapamycin anhydrous gel is a topical immunomodulator that targets the mTOR pathway. Used for Moderate to severe atopic dermatitis.
At a glance
| Generic name | QTORIN 3.9% rapamycin anhydrous gel |
|---|---|
| Sponsor | Palvella Therapeutics, Inc. |
| Drug class | immunosuppressant |
| Target | mTOR |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Rapamycin, the active ingredient in QTORIN, binds to the mTOR complex, inhibiting its activity and leading to immunosuppressive effects. This mechanism is thought to be responsible for the therapeutic benefits of QTORIN in treating atopic dermatitis.
Approved indications
- Moderate to severe atopic dermatitis
Common side effects
- Skin burning sensation
- Skin redness
- Skin itching
Key clinical trials
- A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations (PHASE2)
- SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations (PHASE3)
- A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita (PHASE3)
- A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QTORIN 3.9% rapamycin anhydrous gel CI brief — competitive landscape report
- QTORIN 3.9% rapamycin anhydrous gel updates RSS · CI watch RSS
- Palvella Therapeutics, Inc. portfolio CI